Leqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of US "represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease," says Food and Drug Administration.
Injected drug, lecanemab, slowed the progress of the brain-wasting disease by 27 percent compared to a placebo, meeting the study's main goal, say drugmakers Eisai and Biogen.
US Food and Drug Administration said that the drug developed by Biogen named Aducanumab, or Aduhelm, is the only one that can likely treat the underlying disease as independent advisers urge caution over the treatment.
Subscribe to our Youtube channel for all latest in-depth, on the ground reporting from around the world.
Copyright © 2023 TRT World.